Biofil Chemicals & Pharmaceuticals Q2 FY27 Share Price & Earnings Call Analysis

₹31.39-0.95% today
Market cap
₹51 Cr
P/E
98.21
ROE
-2.83%
Price to sales
2.27
Debt to equity
0.10
52W high / low
₹47.7 / ₹25.8
Sales growth (5Y)
-4.50%
EBITDA margin
3.39%
Net profit margin
-2.01%
Promoter holding
46.79%
Sales (last year)
₹22 Cr

Incorporated in 1993, Biofil Chemicals and Pharmaceuticals Ltd manufactures pharmaceutical bulk drugs[1]

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. 1
  3. 3

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Biofil Chemicals & Pharmaceuticals latest results (Sep 2026)

Revenue

₹2 Cr

-87.67% YoY

Net profit

₹0 Cr

+50% YoY

Operating margin

5.99%

EPS

₹0.07

What management said on the call →

Biofil Chemicals & Pharmaceuticals shareholding (Sep 2026)

Promoters

46.79%

unchanged QoQ

FIIs

0.00%

unchanged QoQ

DIIs

0.08%

unchanged QoQ

Public

53.13%

unchanged QoQ

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹3,041 Cr33.1
240%+Up 2%+₹492 Cr19.6
340%+Up 0–2%₹234 Cr17.8
440%+Flat₹18,347 Cr—
540%+Flat₹8,432 Cr32.4
640%+Flat₹4,295 Cr—

Financials of Biofil Chemicals

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Biofil Chemicals

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +46.82%46.82%46.82%46.82%46.82%46.82%46.82%46.79%46.79%46.79%46.79%46.79%
FIIs +0.00%0.03%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
DIIs +0.08%0.08%0.08%0.08%0.08%0.08%0.08%0.08%0.08%0.08%0.08%0.08%
Public +53.11%53.08%53.11%53.10%53.11%53.11%53.10%53.12%53.13%53.12%53.13%53.13%
No. of Shareholders25,86426,58125,48026,42226,11425,91425,68525,19624,82525,35624,99924,660

Pros & Cons

Biofil Chemicals

Key positives and risks surfaced from the company insights section.

Pros
  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of -4.50% over past five years.
  • Company has a low return on equity of 1.24% over last 3 years.
  • Earnings include an other income of Rs.0.38 Cr.
  • Company has high debtors of 355 days.
Raw Insights
  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of -4.50% over past five years.
  • Company has a low return on equity of 1.24% over last 3 years.
  • Earnings include an other income of Rs.0.38 Cr.
  • Company has high debtors of 355 days.

Financials of Biofil Chemicals

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +17.375.0315.208.442.4114.208.356.4313.540.867.5712.351.67
YoY Sales growth+562.98%+237.58%+11.60%+247.33%-86.13%+182.31%-45.07%-23.82%+461.83%-93.94%-9.34%+92.07%-87.67%
Expenses +17.134.8415.248.132.2913.898.246.4213.420.777.1412.211.57
Operating Profit0.240.19-0.040.310.120.310.110.010.120.090.430.140.10
OPM %1.38%3.78%-0.26%3.67%4.98%2.18%1.32%0.16%0.89%10.47%5.68%1.13%5.99%
Other Income +0.030.030.410.030.020.020.242.830.060.080.110.060.13
Interest0.010.000.020.010.010.010.010.010.000.000.000.000.01
Depreciation0.110.110.080.100.100.100.080.070.070.070.070.070.07
Profit before tax0.150.110.270.230.030.220.262.760.110.100.470.130.15
Tax %20.00%18.18%11.11%26.09%33.33%27.27%23.08%12.68%27.27%30.00%55.32%23.08%26.67%
Net Profit +0.120.090.250.170.020.160.202.410.080.080.210.110.12
EPS in Rs0.070.060.150.100.010.100.121.480.050.050.130.070.07

Financials of Biofil Chemicals

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +5.8613.1713.4512.3623.1329.6935.7522.3830.0440.0433.4028.4022.45
Sales growth-18.27%+124.74%+2.13%-8.10%+87.14%+28.36%+20.41%-37.40%+34.23%+33.29%-16.58%-14.97%-47.20%
Expenses +5.1212.3010.8411.4322.1127.8734.1521.0528.8839.2332.5527.7521.69
Operating Profit0.740.872.610.931.021.821.601.331.160.810.850.650.76
OPM %12.63%6.61%19.41%7.52%4.41%6.13%4.48%5.94%3.86%2.02%2.54%2.29%3.39%
Other Income +0.460.530.140.100.100.170.800.150.100.490.313.080.38
Interest0.210.150.160.150.160.120.070.040.040.040.040.010.01
Depreciation0.250.260.280.300.370.410.410.430.430.400.380.270.28
Profit before tax0.740.992.310.580.591.461.921.010.790.860.743.450.85
Tax %20.27%20.20%22.51%20.69%20.34%17.81%34.90%31.68%29.11%17.44%24.32%19.13%
Net Profit +0.590.781.790.470.481.211.240.700.560.710.562.790.52
EPS in Rs0.360.481.100.290.290.740.760.430.340.440.341.710.32
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials of Biofil Chemicals

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital16.2716.2716.2716.2716.2716.2716.2716.2716.2716.2716.2716.2716.27
Reserves-7.86-5.37-3.58-3.11-2.62-1.39-0.140.561.031.932.515.295.51
Borrowings +2.981.371.431.561.641.190.430.460.520.440.473.022.17
Other Liabilities +2.3611.877.729.448.9326.3016.681.4413.5828.4431.7018.2629.37
Total Liabilities13.7524.1421.8424.1624.2242.3733.2418.7331.4047.0850.9542.8453.32
Fixed Assets +9.068.989.169.2510.2910.099.789.429.008.628.346.946.89
CWIP0.000.000.000.000.000.000.000.000.000.000.000.000.00
Investments0.000.000.000.000.000.000.000.000.000.000.000.000.00
Other Assets +4.6915.1612.6814.9113.9332.2823.469.3122.4038.4642.6135.9046.43
Total Assets13.7524.1421.8424.1624.2242.3733.2418.7331.4047.0850.9542.8453.32

Financials of Biofil Chemicals

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +0.010.140.710.461.260.891.11-0.22-0.112.39-1.92-0.60
Cash from Investing Activity +-0.17-0.19-0.48-0.38-1.41-0.21-0.10-0.07-0.01-0.02-0.101.14
Cash from Financing Activity +0.110.10-0.11-0.02-0.08-0.57-0.83-0.010.02-0.120.002.54
Net Cash Flow-0.050.050.130.06-0.240.120.18-0.30-0.112.25-2.033.07
Free Cash Flow-0.16-0.050.230.08-0.150.681.01-0.29-0.122.37-2.020.54
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit19%33%35%103%134%63%112%8%10%314%-205%9%

Financials of Biofil Chemicals

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days227.35387.45311.00383.31189.84365.25175.81116.94249.08301.10418.77354.59
Inventory Days15.993.467.2938.1121.7324.3748.8524.2016.1124.8139.5256.24
Days Payable198.49400.98304.52341.46156.66373.80178.3911.25168.39268.08366.66239.87
Cash Conversion Cycle44.85-10.0713.7679.9554.9015.8246.27129.8896.8057.8391.63170.96
Working Capital Days-47.9648.5087.65104.8350.8155.6964.12125.25104.2569.37114.09152.17
ROCE %8.59%9.64%18.72%5.06%5.00%10.08%12.20%6.20%4.73%4.94%4.12%2.97%

Biofil Chemicals & Pharmaceuticals: frequently asked questions

What is Biofil Chemicals & Pharmaceuticals share price today?

Biofil Chemicals & Pharmaceuticals last traded at ₹31.39, with a market capitalisation of ₹51 Cr and a P/E ratio of 98.2.

What were Biofil Chemicals & Pharmaceuticals's latest quarterly results?

For the quarter ended Sep 2026, Biofil Chemicals & Pharmaceuticals reported revenue of ₹2 Cr (-87.67% year on year) and net profit of ₹0 Cr, with an operating margin of 5.99%.

Is Biofil Chemicals & Pharmaceuticals's profit growing?

Net profit was ₹0 Cr in Sep 2026 against ₹0 Cr in Sep 2025, a change of +50%.

What is Biofil Chemicals & Pharmaceuticals's EPS?

Biofil Chemicals & Pharmaceuticals's earnings per share for the quarter ended Sep 2026 was ₹0.07.

What is the promoter holding in Biofil Chemicals & Pharmaceuticals?

Promoters held 46.79% of Biofil Chemicals & Pharmaceuticals in Sep 2026 (unchanged versus Jun 2026).

How much do FIIs and DIIs hold in Biofil Chemicals & Pharmaceuticals?

In Sep 2026, foreign institutional investors held 0.00% and domestic institutions (including mutual funds) held 0.08% of Biofil Chemicals & Pharmaceuticals.

What is Biofil Chemicals & Pharmaceuticals's ROE and ROCE?

Biofil Chemicals & Pharmaceuticals's return on equity is -2.83% and its return on capital employed is 2.97%.

Does Biofil Chemicals & Pharmaceuticals pay a dividend?

Biofil Chemicals & Pharmaceuticals's dividend yield is 0% at the current price; see the Biofil Chemicals & Pharmaceuticals dividends page for past payouts.

Which sector does Biofil Chemicals & Pharmaceuticals belong to?

Biofil Chemicals & Pharmaceuticals is in the Pharmaceuticals & Biotechnology sector. Its peer comparison and sector ranking are on this page.

What did Biofil Chemicals & Pharmaceuticals's management say on the latest earnings call?

Arthneeti's analysis of the Q2 FY27 earnings call covers revenue, margins, capex and fundraising guidance from Biofil Chemicals & Pharmaceuticals's management.

How does Arthneeti AI analyse Biofil Chemicals & Pharmaceuticals?

Arthneeti reads Biofil Chemicals & Pharmaceuticals's earnings call transcripts and filings and scores revenue growth, margins, capex and fundraising, then ranks the company against its sector.

What Biofil Chemicals's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Alpa Laboratorie (Q2 FY27)

    Standalone: ₹3,097.56 lacs . Key results statement takeaways from Alpa Laboratories Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Aarey Drugs (Q2 FY27)

    Revenue from Operations for quarter ended 30.09.2026: ₹2,865.24 Lakhs . Key results statement takeaways from Aarey Drugs & Pharmaceuticals Ltd's Q2 FY27 results